- Proprietary cutting-edge multi-specific antibody strategies to ensure exquisite specificity and optimal internalization
- Homogenous glycosylation profile enabled by proprietary NECORTM technology
- Flexible site-specific conjugation schema powered by NECOR TM and site-specific mutations
- Homogenous ADCs with customized DARs (drug-to-antibody ratio) of 2, 4, 6, or 8
- Protease or caspase-dependent peptide linkers to increase tumor accumulation and bystander effect
- Consistency in product from pilot to manufacturing scale
Menu
